REPLIGEN CORP
RGEN evidence brief
What we can confirm
- BioSniper Score:
- 5.8 / 10
- Market Cap:
- $9.51B
What it means
What to watch
Prepared research question
What matters most for RGEN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RGEN
Repligen Corporation (RGEN) is a global life sciences company that develops and commercializes bioprocessing technologies and systems for the manufacture of biological drugs, including monoclonal antibodies, vaccines, and cell and gene therapies [sec · filed 2024-11-18].
Key risk: Forward-looking statement risks
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$9.51B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Repligen Corporation (RGEN) is a global life sciences company that develops and commercializes bioprocessing technologies and systems for the manufacture of biological drugs, including monoclonal antibodies, vaccines, and cell and gene therapies [sec · filed 2024-11-18].
- Cash & equivalents of $606.8M as of 2026-06-30 [sec].
- Total revenue of $204.1M and net income of $5.0M as of 2026-06-30 [sec].
- Shareholders' equity of $2,112.0M as of 2026-06-30 [sec].
- In 2024, the company expanded its 'high probability' (50%+) opportunity funnel, with fourth quarter orders at their highest levels in over two years [sec · filed 2025-04-04].
- The company is positioned to participate in cell and gene therapy production, particularly in the manufacture of plasmids and viral vectors [sec · filed 2024-11-18].
What works
- Strong cash position of $606.8M as of 2026-06-30 provides financial flexibility for operations and investments [sec].
- Positive net income of $5.0M as of 2026-06-30 indicates recent profitability [sec].
- Expanding presence in high-growth modalities like cell and gene therapy, with over 3,000 active clinical trials underway at year-end 2023 [sec · filed 2024-11-18].
- Momentum in orders from CDMOs and Equipment sectors exiting 2024, with fourth quarter orders at their highest levels in over two years [sec · filed 2025-04-04].
What to weigh
- The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated [sec · filed 2024-11-18].
- Historical filings indicate the company has previously incurred operating losses and needed additional capital to support drug development programs [sec · filed 2005-06-14].
- The bioprocessing market recovery post-pandemic has been slower in some sectors, though orders are improving [sec · filed 2025-04-04].
From the filings
Quoted directly from source documents.
Fourth quarter orders at highest levels in over two years
“culminating in fourth quarter orders at their highest levels in over two years.”
SEC filings · April 4, 2025
Positioning in cell and gene therapy market
“We believe we are well positioned to participate in C> production, particularly in the manufacture of plasmids and viral vectors.”
SEC filings · November 18, 2024
Forward-looking statements subject to risks
“Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated”
SEC filings · November 18, 2024
Risks & what to watch (3)›
Key risks
- Forward-looking statement risks — Actual results may differ materially from those anticipated due to identified risk factors [sec · filed 2024-11-18].
- Historical operating losses — The company has previously incurred operating losses and needed additional capital to fund drug development [sec · filed 2005-06-14].
- Market recovery uncertainty — Some key market sectors have been slower to recover post-pandemic, though orders are improving [sec · filed 2025-04-04].
What to watch
- Continued order momentum from CDMOs and Equipment sectors as a sign of market recovery [sec · filed 2025-04-04].
- Expansion of the 'high probability' opportunity funnel and its conversion into revenue [sec · filed 2025-04-04].
- Progress in cell and gene therapy product adoption, particularly in plasmid and viral vector manufacturing [sec · filed 2024-11-18].
- Financial performance trends, including revenue and net income, given the recent positive net income [sec].
Sources: SEC filings · Generated September 29, 2026 · How we verify sources →
Run REPLIGEN CORP through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available REPLIGEN CORP facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.40 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 4 sells (180d)
Financials
Short Interest
as of Apr 19, 2026- % of float
- 9.9%
- Days to cover
- 6.4
- Shares short
- 5,556,333
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RGEN short interestGovernance
Frequently asked questions
What is the AI investment thesis for REPLIGEN CORP?
Repligen Corporation (RGEN) is a global life sciences company that develops and commercializes bioprocessing technologies and systems for the manufacture of biological drugs, including monoclonal antibodies, vaccines, and cell and gene therapies [sec · filed 2024-11-18].
Who is the CEO of REPLIGEN CORP?
Mr. Olivier Loeillot is the chief executive officer of REPLIGEN CORP (RGEN).
Where is REPLIGEN CORP headquartered?
REPLIGEN CORP (RGEN) is headquartered in Waltham, MA, United States.
What therapeutic areas does REPLIGEN CORP focus on?
REPLIGEN CORP develops therapies across Oncology, Gene Therapy, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.